EP1503801A4 - Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands - Google Patents

Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands

Info

Publication number
EP1503801A4
EP1503801A4 EP03727872A EP03727872A EP1503801A4 EP 1503801 A4 EP1503801 A4 EP 1503801A4 EP 03727872 A EP03727872 A EP 03727872A EP 03727872 A EP03727872 A EP 03727872A EP 1503801 A4 EP1503801 A4 EP 1503801A4
Authority
EP
European Patent Office
Prior art keywords
polypeptides
blood
brain barrier
invasive delivery
vivo selection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03727872A
Other languages
German (de)
French (fr)
Other versions
EP1503801A2 (en
Inventor
Ian A Ferguson
Hiroaki Tani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delgene Inverstor Services Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPS1935A external-priority patent/AUPS193502A0/en
Priority claimed from US10/188,184 external-priority patent/US20030083299A1/en
Application filed by Individual filed Critical Individual
Publication of EP1503801A2 publication Critical patent/EP1503801A2/en
Publication of EP1503801A4 publication Critical patent/EP1503801A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP03727872A 2002-04-26 2003-04-28 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands Withdrawn EP1503801A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US188184 1980-09-18
AUPS193502 2002-04-26
AUPS1935A AUPS193502A0 (en) 2002-04-26 2002-04-26 Molecules that mediate internalisation in cells
US10/188,184 US20030083299A1 (en) 2000-11-04 2002-07-02 Non-invasive delivery of polypeptides through the blood-brain barrier
PCT/IB2003/002371 WO2003091387A2 (en) 2002-04-26 2003-04-28 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands

Publications (2)

Publication Number Publication Date
EP1503801A2 EP1503801A2 (en) 2005-02-09
EP1503801A4 true EP1503801A4 (en) 2006-02-08

Family

ID=29271266

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03727872A Withdrawn EP1503801A4 (en) 2002-04-26 2003-04-28 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands

Country Status (4)

Country Link
EP (1) EP1503801A4 (en)
JP (2) JP2005535580A (en)
CA (1) CA2483980C (en)
WO (1) WO2003091387A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2431348B (en) * 2004-06-23 2009-12-30 Ian A Ferguson Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders
WO2007086587A1 (en) * 2006-01-24 2007-08-02 Kagoshima University Agent for targeting drug to cerebral neuron
JP2011024499A (en) * 2009-07-27 2011-02-10 Nec Soft Ltd Method for producing nucleic acid, tag nucleic acid for delivery which can organ-specifically deliver delivery object, and use thereof
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
CN113838541B (en) * 2021-09-29 2023-10-10 脸萌有限公司 Method and apparatus for designing ligand molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004695A1 (en) * 1992-08-14 1994-03-03 The Rockefeller University Herpesviral defective vector with rat preproenkephalin gene promoter

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770797B2 (en) * 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004695A1 (en) * 1992-08-14 1994-03-03 The Rockefeller University Herpesviral defective vector with rat preproenkephalin gene promoter

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BERRY M ET AL: "GENE THERAPY FOR CENTRAL NERVOUS SYSTEM REPAIR", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 3, no. 4, August 2001 (2001-08-01), pages 338 - 349, XP009055046, ISSN: 1464-8431 *
GLORIOSO J C ET AL: "Use of HSV vectors to modify the nervous system", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 5, no. 2, 2002, pages 289 - 295, XP002278729, ISSN: 1367-6733 *
KASSNER P D ET AL: "Genetic selction of phage engineered for receptor-mediated gene transfer to mammalian cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 264, 1999, pages 921 - 928, XP002189963, ISSN: 0006-291X *
KAY M A ET AL: "VIRAL VECTORS FOR GENE THERAPY: THE ART OF TURNING INFECTIOUS AGENTS INTO VEHICLES OF THERAPEUTICS", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 7, no. 1, January 2001 (2001-01-01), pages 33 - 40, XP008042487, ISSN: 1078-8956 *
MAZARAKIS N D ET AL: "RABIES VIRUS GLYCOPROTEIN PSEUDOTYPING OF LENTIVIRAL VECTORS ENABLES RETROGRADE AXONAL TRANSPORT AND ACCESS TO THE NERVOUS SYSTEM AFTER PERIPHERAL DELIVERY", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 19, 15 September 2001 (2001-09-15), pages 2109 - 2121, XP001058914, ISSN: 0964-6906 *
PALMER J A ET AL: "Development and optimization of herpes simplex virus vectors for multiple long-term delivery to the peripheral nervous system", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 12, June 2000 (2000-06-01), pages 5604 - 5618, XP002164866, ISSN: 0022-538X *
PICKARD GARY E ET AL: "Intravitreal injection of the attenuated pseudorabies virus PRV Bartha results in infection of the hamster suprachiasmatic nucleus only by retrograde transsynaptic transport via autonomic circuits", JOURNAL OF NEUROSCIENCE, vol. 22, no. 7, 1 April 2002 (2002-04-01), pages 2701 - 2710, XP002358460, ISSN: 0270-6474 *
See also references of WO03091387A2 *
SOUDAIS CLAIRE ET AL: "Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo", FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, vol. 15, no. 12, October 2001 (2001-10-01), pages 2283 - 2285, XP002347771, ISSN: 0892-6638 *
WANG S ET AL: "Transgene expression in the brain stem effected by intramuscular injection of polyethylenimine/DNA complexes.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. MAY 2001, vol. 3, no. 5 Pt 1, May 2001 (2001-05-01), pages 658 - 664, XP002358454, ISSN: 1525-0016 *
YAMAMURA J ET AL: "Long-term gene expression in the anterior horn motor neurons after intramuscular inoculation of a live herpes simplex virus vector", GENE THERAPY, vol. 7, no. 11, June 2000 (2000-06-01), pages 934 - 941, XP002358455, ISSN: 0969-7128 *
YAN Q ET AL: "Retrograde transport of nerve growth factor (NGF) in motoneurons of developing rats: assessment of potential neurotrophic effects.", NEURON. JUN 1988, vol. 1, no. 4, June 1988 (1988-06-01), pages 335 - 343, XP002358456, ISSN: 0896-6273 *

Also Published As

Publication number Publication date
EP1503801A2 (en) 2005-02-09
JP2013136586A (en) 2013-07-11
WO2003091387A2 (en) 2003-11-06
JP2005535580A (en) 2005-11-24
CA2483980C (en) 2013-07-16
CA2483980A1 (en) 2003-11-06
WO2003091387A3 (en) 2004-01-08
WO2003091387A9 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
AU2002352344A8 (en) Medicament delivery assembly
AU8964001A (en) Intracardiac blood pump
HK1079718A1 (en) Intracardiac drug delivery
HK1061534A1 (en) Implantable drug delivery pump
EP1594477A4 (en) Active drug delivery in the gastrointestinal tract
AU6627201A (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
HK1078851A1 (en) 2-Indolinone-monoethanesulphonate and the use thereof in preparing a pharmaceutical composition
IL159275A0 (en) Phenylsulfonyl-1, 3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
IL152593A0 (en) Liposome drug delivery
IL157580A0 (en) Inhalation drug combination
HK1080015A1 (en) Drug delivery assembly
HK1065700A1 (en) Use of gnrh antagonists in the preparation of a medicament for preventing diabetes
EP1578769A4 (en) Peptides and the use thereof in darkening the skin
EP1503801A4 (en) Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
GB0130140D0 (en) Improvements in and relating to medicament delivery service
EP1421954A4 (en) Materials sustainedly releasing drug in vivo
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
GB0201032D0 (en) Delivery of reactive agents via bi-layer structures for use in shelf-stable products
PL1660532T3 (en) Fusion polypeptides, and use thereof in antivascular tumor therapy
EP1449644A4 (en) Layered product and medical supply comprising the layered product
GB9930160D0 (en) Drug delivery
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
GB0210020D0 (en) Medical agent delivery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20051223

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DELGENE INVERSTOR SERVICES PTY LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150421